Navigation Links
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Date:11/27/2012

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation (dUCBT) for hematologic malignancy.  The advancement of ProHema into later-stage development builds upon positive results from a Phase 1b single-center study, interactions with the U.S. Food and Drug Administration and refinements to the product manufacturing process.  The previously completed Phase 1b study achieved its primary objective of demonstrating safety and tolerability.  The study also established early clinical proof-of-concept – trends of accelerated neutrophil recovery, improved 100-day survival and low rates of graft-versus-host disease were evident, and durable and preferential reconstitution with ProHema occurred in 10 of 12 evaluable patients.  ProHema is produced through a proprietary, two-hour, ex vivo modulation process, which has been shown to significantly activate key biological pathways involved in hematopoietic stem cell homing, proliferation and survival in preclinical models.

"Allogeneic umbilical cord blood transplantation holds great promise as a potentially curative treatment for children and adults with hematologic malignancies and many other life-threatening, non-malignant disorders," said Christian Weyer, M.D., M.A.S., President and Chief Executive Officer of Fate Therapeutics.  "ProHema is being developed with the intent to improve outcomes in patients undergoing cord blood transplantation by facilitating both accelerated engraftment and durable reconstitution using a simple, point-of-care, ex vivo modulation process. The initiation of Phase 2 marks an important milestone for the company and bri
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
3. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
4. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
5. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
6. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
7. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
8. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
9. Echo Therapeutics Announces Third Quarter 2012 Financial Results
10. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
11. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 According to the ... Pre-packed, Analytical, Preparative), by Material (Metal, Glass, Plastic), by ... Forecast to 2018", published by MarketsandMarkets, the Chiral Chromatography ... is poised to grow at a CAGR of 5.2% ... Browse 90 market data tables and 15 ...
(Date:9/2/2014)... ALISO VIEJO, Calif. , Sept. 2, 2014  Avanir ... company management will present an overview of the company at ... York . , Presentation date: Tuesday September ... A live webcast and 30-day archive of ... About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, ...
(Date:9/2/2014)... 2014  EMD Serono, Inc., a subsidiary of Merck ... that Drew Young has joined the company ... capacity, he will be responsible for leading the strategic ... future products.   Bringing more than 20 years ... efforts at pharmaceutical and biotech companies, Mr. Young comes ...
Breaking Medicine Technology:Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4
(Date:9/2/2014)... (PRWEB) September 03, 2014 Recently, BambooIndustry.com, ... its new range of strand woven bamboo floors ... more clients and show its appreciation to the frequent ... products. , In addition to strand woven floors, ... clients, including hand scraped floors, click strand woven floors, ...
(Date:9/2/2014)... Atlanta, Ga. (PRWEB) September 02, 2014 ... hosted by, respectively, top-industry professionals Carey Lewis ... each person auditioning, seeking those who have the desire ... chosen for a callback, performers could be invited to ... SHINE convention. , Charlotte, NC – Saturday, Sept. 6, ...
(Date:9/2/2014)... 2014 The Wm. Jennings Bryan Dorn Veterans ... town hall meeting for Veterans and their families on September ... fair to provide Veterans with valuable healthcare and benefit information,” ... will provide a forum where we can gather important input ... outreach fair will be held 4:45 p.m. to 5:45 p.m. ...
(Date:9/2/2014)... In a large population-based study of randomly selected ... impairment (MCI) occurred twice more often in individuals ... strong association was only observed in middle-aged participants ... the association vanished. This study is published in ... The concept of MCI describes an intermediate state ...
(Date:9/2/2014)... Operators in the Community Services industry ... care and counsel for those in need. In 2014-15, ... derive $39.4 billion in revenue, which includes a combination ... five years through 2014-15, the subdivision is forecast to ... of 4.1% in 2014-15. , As the population ages ...
Breaking Medicine News(10 mins):Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Using tiny gold particles embedded with dyes, researchers have ... of a living animal. These tools may allow doctors ... , Studded with antibody fragments called ScFv peptides that ... after their injection into a mouse. When illuminated with ...
... simple steps can help you cope , , SATURDAY, Dec. 22 ... of joy and celebration for many, it can trigger holiday ... to holiday blues, there are things you can do to ... Mood Disorders Program at the Jefferson Medical College of Thomas ...
... Kansas Hospital Offers Tips to Guard Against Influenza as ... ... While it may be too late to,purchase certain must-have gifts ... shot. The World Health Organization (WHO) and,National Respiratory and Enteric Virus ...
... PCYC ) today announced that it has received a ... for the company,s,new drug application (NDA) for Xcytrin(R) (motexafin ... (NSCLC) patients with brain,metastases. The NDA for use of ... filed with the FDA in April 2007., According ...
... indications than any other ... drug-eluting stent, ... announced today that its TAXUS(R) Liberte(TM),paclitaxel-eluting coronary stent system has received ... submitted,data showing the TAXUS Liberte stent has benefited diabetic patients with,coronary ...
... considered, protected, HARRISBURG, Pa., Dec. 21 To ... Joel,Ario today announced that the Insurance Department will hold ... the proposed consolidation of,Independence Blue Cross and Highmark Inc., ... would be protected in,any transaction of this type, so ...
Cached Medicine News:Health News:Gold nanoparticle probes may allow earlier cancer detection 2Health News:Gold nanoparticle probes may allow earlier cancer detection 3Health News:Maintaining Routine Can Chase Holiday Blues Away 2Health News:Attention Last-Minute Shoppers: Flu Shots Still Available 2Health News:Attention Last-Minute Shoppers: Flu Shots Still Available 3Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 2Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 2Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 4Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 5Health News:Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross 2
... Chrome-plated metal frames ... ensures optimal cleanliness and ... stools come with user-friendly ... height adjustment. Fixed footring ...
... The ideal modular cleanroom for ... applications that require cleanliness (to Class ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ...
... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
Inquire...
Medicine Products: